Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Endo180 CRISPR/Cas9 KO Plasmid (h): sc-403483
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Endo180 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Endo180 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Endo180 Antibody (B-10): sc-271148
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Endo180 CRISPR/Cas9 KO Plasmid (h) | sc-403483 | 20 µg | $397.00 |
Overview
MRC2 encodes Endo180 (also known as uPARAP), a transmembrane endocytic receptor of the mannose receptor family that binds and internalizes collagen for lysosomal degradation. Endo180 couples extracellular matrix remodeling to cell adhesion and migration by regulating collagen turnover, integrin-associated signaling, and trafficking pathways linked to endocytosis. Through its role in collagen uptake and matrix dynamics, Endo180 contributes to stromal remodeling and invasive cellular phenotypes often studied in cancer biology, fibrosis, and tissue repair contexts. Dysregulated MRC2/Endo180 activity has been associated with altered extracellular matrix homeostasis and microenvironmental changes relevant to disease mechanisms.
Endo180 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MRC2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MRC2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MRC2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Endo180 protein expression.
This CRISPR knockout system enables efficient generation of MRC2-deficient cell models for investigation of Endo180 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MRC2 exon(s) critical for Endo180 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MRC2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Endo180 CRISPR/Cas9 KO Plasmid (h) and Endo180 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MRC2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Endo180 HDR Plasmid (h) and Endo180 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MRC2 homology arms to support homology-directed repair at defined MRC2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.